CN110545838A - 用于从药物递送装置施用致恶心化合物的设备和方法 - Google Patents

用于从药物递送装置施用致恶心化合物的设备和方法 Download PDF

Info

Publication number
CN110545838A
CN110545838A CN201880026107.XA CN201880026107A CN110545838A CN 110545838 A CN110545838 A CN 110545838A CN 201880026107 A CN201880026107 A CN 201880026107A CN 110545838 A CN110545838 A CN 110545838A
Authority
CN
China
Prior art keywords
nausea
causing compound
causing
subject
long
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880026107.XA
Other languages
English (en)
Chinese (zh)
Inventor
A·扬
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intacia Pharmaceutical Co
Original Assignee
Intacia Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intacia Pharmaceutical Co filed Critical Intacia Pharmaceutical Co
Publication of CN110545838A publication Critical patent/CN110545838A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201880026107.XA 2017-03-08 2018-03-08 用于从药物递送装置施用致恶心化合物的设备和方法 Pending CN110545838A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762468399P 2017-03-08 2017-03-08
US62/468,399 2017-03-08
PCT/US2018/021594 WO2018165462A1 (en) 2017-03-08 2018-03-08 Apparatus and methods for administration of a nauseogenic compound from a drug delivery device

Publications (1)

Publication Number Publication Date
CN110545838A true CN110545838A (zh) 2019-12-06

Family

ID=61692164

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880026107.XA Pending CN110545838A (zh) 2017-03-08 2018-03-08 用于从药物递送装置施用致恶心化合物的设备和方法

Country Status (10)

Country Link
US (1) US20200188479A1 (https=)
EP (1) EP3592376A1 (https=)
JP (2) JP2020510028A (https=)
KR (1) KR20190126335A (https=)
CN (1) CN110545838A (https=)
AU (1) AU2018231249A1 (https=)
CA (1) CA3055759A1 (https=)
IL (1) IL269001A (https=)
MX (1) MX2019010651A (https=)
WO (1) WO2018165462A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117143242A (zh) * 2023-10-30 2023-12-01 南京佰抗生物科技有限公司 抗Galectin-3蛋白的单克隆抗体组合物及应用

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2712761C1 (ru) * 2019-07-02 2020-01-31 Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр Российской академии наук" (Томский НИМЦ) Средство для стимуляции регенерации эндотелия легких при сочетании метаболического синдрома и хронической обструктивной болезни легких
JP2023522944A (ja) * 2020-04-20 2023-06-01 アイツーオー・セラピューティクス・インコーポレイテッド １型糖尿病患者に優れた血糖制御をもたらすためのヒトアミリンアナログポリペプチドの使用
US20250268231A1 (en) * 2024-02-27 2025-08-28 Ashop Commerce Pty Ltd. System and method for monitoring and controlling pet activity

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120208755A1 (en) * 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
CN102686741A (zh) * 2009-09-28 2012-09-19 精达制药公司 基本稳态药物递送的快速建立和/或终止

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK155694A3 (en) * 1992-06-15 1995-05-10 Pfizer Glucagon-like peptide, insulinotropin derivatives, method of their preparation, pharmaceutical agent containing and using these matters
US5609885A (en) 1992-09-15 1997-03-11 Alza Corporation Osmotic membrane and delivery device
US6156331A (en) 1996-02-02 2000-12-05 Alza Corporation Sustained delivery of an active agent using an implantable system
US6395292B2 (en) 1996-02-02 2002-05-28 Alza Corporation Sustained delivery of an active agent using an implantable system
ES2233768T3 (es) 1996-02-02 2005-06-16 Alza Corporation Liberacion prolongada de un agente activo utilizando un sistema implantable.
US6132420A (en) 1996-02-02 2000-10-17 Alza Corporation Osmotic delivery system and method for enhancing start-up and performance of osmotic delivery systems
US6261584B1 (en) 1996-02-02 2001-07-17 Alza Corporation Sustained delivery of an active agent using an implantable system
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
US7235627B2 (en) 1996-08-30 2007-06-26 Novo Nordisk A/S Derivatives of GLP-1 analogs
ZA981610B (en) 1997-03-24 1999-08-26 Alza Corp Self adjustable exit port.
MY125849A (en) 1997-07-25 2006-08-30 Alza Corp Osmotic delivery system, osmotic delivery system semipermeable body assembly, and method for controlling delivery rate of beneficial agents from osmotic delivery systems
ES2182379T3 (es) 1997-12-22 2003-03-01 Alza Corp Membrana de regulacion del regimen de liberacion para dispositivos de administracion controlada de farmacos.
JP4173635B2 (ja) 1997-12-29 2008-10-29 インターシア セラピューティクス，インコーポレイティド 膜プラグ保持機構を有する浸透供給装置
WO1999033449A1 (en) 1997-12-30 1999-07-08 Alza Corporation Beneficial agent delivery system with membrane plug
JP2002512175A (ja) * 1998-02-27 2002-04-23 ノボ ノルディスク アクティーゼルスカブ Ｇｌｐ−１類似体の誘導体類
JP4383674B2 (ja) 1998-12-31 2009-12-16 インターシア セラピューティクス，インコーポレイティド 空間効率のよいピストンを有する浸透圧送達システム
US6528486B1 (en) 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
CA2402637C (en) 1999-12-21 2007-04-10 Alza Corporation Valve for osmotic devices
WO2001087322A2 (en) * 2000-05-17 2001-11-22 Bionebraska, Inc. Peptide pharmaceutical formulations
US7163688B2 (en) 2001-06-22 2007-01-16 Alza Corporation Osmotic implant with membrane and membrane retention means
MXPA05000224A (es) 2002-06-26 2005-06-03 Alza Corp Piston de volumen eficiente, minimamente deformable, para sistemas de suministro osmotico de farmacos.
US7014636B2 (en) 2002-11-21 2006-03-21 Alza Corporation Osmotic delivery device having a two-way valve and a dynamically self-adjusting flow channel
ATE387236T1 (de) 2003-03-31 2008-03-15 Alza Corp Osmotische pumpe mit mitteln zum ableiten des innendrucks
US20050175701A1 (en) 2004-02-10 2005-08-11 Alza Corporation Capillary moderator for osmotic delivery system
US7456254B2 (en) 2004-04-15 2008-11-25 Alkermes, Inc. Polymer-based sustained release device
CA2595457A1 (en) * 2005-01-25 2006-08-03 Microchips, Inc. Control of drug release by transient modification of local microenvironments
TWI372629B (en) 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
ES2736184T3 (es) 2005-08-19 2019-12-26 Amylin Pharmaceuticals Llc Exendina para el tratamiento de la diabetes y la reducción del peso corporal
ES2495741T3 (es) * 2006-04-20 2014-09-17 Amgen, Inc Compuestos de GLP-1
MX2008014870A (es) 2006-05-30 2009-02-12 Intarcia Therapeutics Inc Modulador de flujo para sistema de suministro osmotico con canal interno de dos piezas.
EP2049081B1 (en) 2006-08-09 2012-11-14 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies
WO2008061355A1 (en) * 2006-11-24 2008-05-29 Matregen Corp. Glp-1 depot systems, and methods of manufacture and uses thereof
DK2240155T3 (da) 2008-02-13 2012-09-17 Intarcia Therapeutics Inc Indretninger, formuleringer og fremgangsmåder til levering af flere gavnlige midler
EP2512518A1 (en) * 2009-12-16 2012-10-24 Novo Nordisk A/S Glp-1 receptor agonist compounds with a modified n-terminus
CA3070513C (en) * 2010-05-05 2023-01-03 Boehringer Ingelheim International Gmbh A dpp-4 inhibitor for use in treatment of skin-alterations or necrosis
WO2013083826A2 (en) * 2011-12-09 2013-06-13 Novo Nordisk A/S Glp-1 agonists
US8575091B1 (en) 2012-04-19 2013-11-05 Novo Nordisk A/S Amylin analogues and pharmaceutical compositions thereof
SG11201508469YA (en) 2013-05-02 2015-11-27 Glaxosmithkline Ip Dev Ltd Therapeutic peptides
US10479868B2 (en) * 2014-09-04 2019-11-19 Nano Precision Medical, Inc. Polymeric stabilizing formulations
RU2760007C2 (ru) * 2016-05-16 2021-11-22 Интарсия Терапьютикс, Инк. Полипептиды, селективные к рецепторам глюкагона, и способы их применения
WO2017200944A1 (en) * 2016-05-16 2017-11-23 Intarcia Therapeutics, Inc. Glucagon receptor/glp-1 receptor selective analog polypeptides and methods of use thereof
CN110225762A (zh) * 2017-01-03 2019-09-10 因塔西亚制药公司 包括glp-1受体激动剂的连续施用和药物的共同施用的方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102686741A (zh) * 2009-09-28 2012-09-19 精达制药公司 基本稳态药物递送的快速建立和/或终止
US20120208755A1 (en) * 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JULIO ROSENSTOCK等: "Potential of Albiglutide, a Long-Acting GLP-1 Receptor Agonist, in Type 2 Diabetes A randomized controlled trial exploring weekly, biweekly, and monthly dosing" *
PHARMACOKINETICS AND TOLERABILITY OF EXENATIDE DELIVERED BY 7-DAY CONTINUOUS SUBCUTANEOUS INFUSION IN HEALTHY VOLUNTEERS等: "Pharmacokinetics and Tolerability of Exenatide Delivered by 7-Day Continuous Subcutaneous Infusion in Healthy Volunteers" *
ROBERT R HENRY等: "A Randomized, Open-Label, Multicenter, 4-Week Study to Evaluate the Tolerability and Pharmacokinetics of ITCA 650 in Patients With Type 2 Diabetes" *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117143242A (zh) * 2023-10-30 2023-12-01 南京佰抗生物科技有限公司 抗Galectin-3蛋白的单克隆抗体组合物及应用

Also Published As

Publication number Publication date
IL269001A (en) 2019-10-31
AU2018231249A1 (en) 2019-09-26
JP2023061945A (ja) 2023-05-02
US20200188479A1 (en) 2020-06-18
WO2018165462A1 (en) 2018-09-13
KR20190126335A (ko) 2019-11-11
JP2020510028A (ja) 2020-04-02
CA3055759A1 (en) 2018-09-13
EP3592376A1 (en) 2020-01-15
MX2019010651A (es) 2020-01-13

Similar Documents

Publication Publication Date Title
JP6835933B2 (ja) 実質的な定常状態薬物送達の迅速な確立及び／又は停止
JP7354350B2 (ja) グルカゴン受容体選択的ポリペプチド及びその使用方法
US10363287B2 (en) Method of manufacturing an osmotic delivery device
JP2023061945A (ja) 薬物送達デバイスから吐き気誘発性化合物の投与のための装置及び方法
TW202028228A (zh) 人類澱粉素(amylin)類似物多肽及使用方法
AU2014280920B2 (en) Rapid establishment and/or termination of substantial steady-state drug delivery
US11246913B2 (en) Suspension formulation comprising an insulinotropic peptide
HK1245156A1 (en) Rapid establishment and/or termination of substantial steady-state drug delivery
HK1172657B (en) Rapid establishment and/or termination of substantial steady-state drug delivery

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20191206